Novozymes Partnering With ProMetic Life Sciences Inc.
Drug Discovery & Development - April 01, 2010

Novozymes (Copenahgen, Denmark) and ProMetic Life Sciences Inc. (Montreal) announced that they have entered into a strategic alliance regarding proprietary albumin purification technology based upon a synthetic-ligand affinity adsorbent developed by ProMetic’s UK subsidiary, ProMetic BioSciences Ltd. The purification technology has been designed for the rapid and cost-effective development of Novozymes’ albufuse albumin-fusion molecules.

Under the terms of the co-marketing alliance the companies will jointly promote the use of a new synthetic-ligand affinity adsorbent, marketed under the trade-name AlbuPure, as a platform approach for the purification of albumin and albumin-fusion proteins. ProMetic will be the exclusive manufacturer and supplier of AlbuPure, however both parties will retain ownership of their respective technologies and both Novozymes and ProMetic will have the right to market AlbuPure.

ProMetic and Novozymes Biopharma, a subsidiary of Novozymes, have collaborated on the development of AlbuPure, which was derived from ProMetic’s Mimetic Ligand technology and targeted at the capture and purification of recombinant albumin proteins produced in yeast. AlbuPure binds specifically to the albumin portion of the molecule and so can be used for the purification of any albufuse albumin-fusion protein.

Novozymes Biopharma has a wealth of experience in the development of albumin-fusion proteins, having pioneered the albufuse technology, which is widely licensed for the manufacture of this increasingly important class of protein therapeutics. The market for biopharmaceutical proteins is estimated to be approximately $80 billion and growing at more than 10% per annum.

According to Dr. Dave Mead, Novozymes Biopharma’s Business Development Director: "Novozymes Biopharma has established itself as the market leader for recombinant albumin expression alongside its unique albufuse technology. This alliance with ProMetic will enable us to expand the technology package offered to our clients to include both protein expression and protein purification technology for albumin-fusion proteins. The availability of a robust affinity capture step, fully supported by Novozymes Biopharma and ProMetic, will provide significant advantages to our clients, including reduced development times and simplified high-yield manufacturing processes. The AlbuPure development builds on a good and long-standing relationship between our two companies."

Drug Discovery & Development magazine

News & Events

  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • in vivo Pharmacodynamic Assay Trevigen offers a validated assay with higher sensitivity and... Read more>>
  • Mapping Technique Speeds Finding Specific Genes A Purdue University scientist was part of a... Read more>>
  • Proximagen Signs Deal With Upsher-Smith Proximagen Neuroscience plc, a biotechnology company... Read more>>
  • U.S. Food & Drug Administration (FDA) New and Generic Drug Approvals Calan (verapamil h... Read more>>
  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • GSK Receives EMEA Approval for Duodart LONDON (AP) - Pharmaceutical company GlaxoSmithKline... Read more>>